<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969201</url>
  </required_header>
  <id_info>
    <org_study_id>13EU/FSH01</org_study_id>
    <nct_id>NCT01969201</nct_id>
  </id_info>
  <brief_title>FSH in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles</brief_title>
  <official_title>Randomised Clinical Trial Comparing Highly Purified FSH Formulation (Fostimon®) and Recombinant FSH (Gonal-F®) in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety
      of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled
      ovarian hyperstimulation in a GnRH-antagonist cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A clinical pregnancy is defined as a pregnancy showing ultrasound embryonic heart activity at 8 weeks of gestation;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of follicles &gt;16 mm on the day of hCG injection</measure>
    <time_frame>10-15 days after starting FSH stimulation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of oocytes retrieved</measure>
    <time_frame>2-3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>2-3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>On culture day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of the embryos will be evaluated just before embryo transfer on Day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive serum pregnancy test</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two weeks after embryo transfer, a serum pregnancy test will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery rate</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative pregnancy rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients who will not get pregnant during the study, will be allowed to perform a frozen embryo transfer. Cumulative pregnancy rate will include also pregnancies achieved after a frozen embryo transfer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Fostimon®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urofollitrophin</intervention_name>
    <arm_group_label>Fostimon®</arm_group_label>
    <other_name>human derived follicle stimulation hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitrophin alpha</intervention_name>
    <arm_group_label>Gonal-F®</arm_group_label>
    <other_name>Recombinant follicle stimulation hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-38 years old;

          -  BMI: 18-28 kg/m2;

          -  Less than 3 previously completed IVF cycles;

          -  Basal FSH &lt;10 IU/L and E2 &lt;80 pg/ml;

          -  TSH &lt; 2.5 mIU/L

          -  &gt;10 antral follicles 2-10 mm in size for both ovaries combined

          -  AMH: &gt;1 ng/ml (7.15 pmol/l) and &lt;4 ng/ml (28.6 pmol/l)

          -  Presence and adequate visualization of both ovaries;

          -  Within 12 months of the beginning of the study, uterine cavity consistent with
             expected normal function as assessed through transvaginal ultrasound,
             hysterosalpingogram, sonohysterogram or hysteroscopic examination;

        Exclusion Criteria:

          -  Primary ovarian failure or women known as poor responders;

          -  PCO and PCOS;

          -  Severe OHSS in a previous COH cycle;

          -  Uterine malformation that may impair the possibility to get pregnant;

          -  Ovarian cysts &gt;10 mm;

          -  Hydrosalpinx that have not been surgically removed or ligated;

          -  Endometriosis stage 3 or 4;

          -  Oocyte donation;

          -  Severe male factor;

          -  Pathologies associated with any contraindication of being pregnant;

          -  History of recurrent miscarriage (more than 3 previous miscarriages);

          -  Hypersensitivity to the study medication;

          -  Abnormal bleeding of undetermined origin;

          -  Uncontrolled thyroid or adrenal dysfunction;

          -  Neoplasias;

          -  Severe impairment of renal and/or hepatic function.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Barri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Universitari Dexeus, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Blockeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara PS Cometti, PHD</last_name>
    <email>barbara.cometti@ibsa.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Blockeel</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Blockeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL- Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Wyns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Omodei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca'Granda, Osp Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edgardo Somigliana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Candiani</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Papaleo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli 'Federico II'</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe De Placido</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Battista La Sala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica IVI Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Munoz</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Barri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Barri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ginefiv Clínica de Fertilidad</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Verdù</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Verdù, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad (IVI)</name>
      <address>
        <city>Sevilla</city>
        <zip>40011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cinzia Caligara</last_name>
    </contact>
    <investigator>
      <last_name>Cinzia Caligara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde</name>
      <address>
        <city>Bern</city>
        <state>Be</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micheal von Wolf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian De Geyter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uludag University</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ata Baris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erol Tavmergen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midland Fertility Services</name>
      <address>
        <city>Aldridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Lockwood</last_name>
    </contact>
    <investigator>
      <last_name>Gillian Lockwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vitro fertilization (IVF)</keyword>
  <keyword>Assisted reproduction technologies (ART)</keyword>
  <keyword>GnRH-antagonist</keyword>
  <keyword>Follicle stimulating hormone (FSH)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
